A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).

Add Yahoo as a preferred source to see more of our stories on Google. A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced ...

Explore surgical options for metastatic bladder cancer, including radical cystectomy and metastasectomy. Learn how surgery can improve survival and quality of life.

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Bladder cancer trials of antibody-drug conjugates may change the standard for neoadjuvant therapy away from dependence on cisplatin chemotherapy.

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...

Transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus were used to construct a 12-gene ARG-based prognostic signature through LASSO and Cox regression ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. People with color blindness ...

Oncologists reveal the number-one sign of bladder cancer, plus how to tell cancer apart from more common issues such as a ...